Download Files:

WYE-687

SKU HY-15271-10 mg Category Tags , ,

$70$602

Products Details

Product Description

– WYE-687 is an ATP-competitive mTOR inhibitor with an IC50 of 7 nM. WYE-687 concurrently inhibits activation of mTORC1 and mTORC2. WYE-687 also inhibits PI3Kα and PI3Kγ with IC50s of 81 nM and 3.11 μM, respectively.

Web ID

– HY-15271

Storage Temperature

– -20°C, 3 years; 4°C, 2 years (Powder)

Shipping

– Room Temperature

Applications

– Cancer-Kinase/protease

Molecular Formula

– C28H32N8O3

Citations

– Biosci Rep. 2019 Dec 20;39(12):BSR20191041.|Molecules. 2020 Apr 23;25(8):1980.|Sci Rep. 2022 Apr 12;12(1):6090.

References

– [1]Yu K, et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009 Aug 1;69(15):6232-40.|[2]Cheng F, et al. Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent. Biochem Biophys Res Commun. 2016 Feb 5;470(2):324-330.

CAS Number

– 1062161-90-3

Molecular Weight

– 528.61

Compound Purity

– 98.10

SMILES

– O=C(OC)NC1=CC=C(C2=NC(N3CCOCC3)=C4C(N(C5CCN(CC6=CC=CN=C6)CC5)N=C4)=N2)C=C1

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)

Target

– mTOR;PI3K

Isoform

– mTOR;mTORC1;mTORC2;PI3Kα;PI3Kγ

Pathway

– PI3K/Akt/mTOR

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.